Purified peanut protein extract for peanut hypersensitivity

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 3 registered trials.

Why this status

  1. 21 Feb 2023: Trial started, NCT05741476
  2. 23 Feb 2023: Trial registered, NCT05741476

The trials

NCT01891136: Oral Peanut Immunotherapy for Peanut Allergic Patients

State
Completed
Phase
Early Phase 1
People
36 taking part
Started
Apr 2004
Primary completion
Nov 2014
Arms
Peanut protein
Results
None posted
  1. 2 Jul 2013: Trial registered

NCT01987817: Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT

State
Completed
Phase
Phase 2
People
56 taking part
Started
6 Feb 2014
Primary completion
7 Jan 2015
Arms
AR101 powder provided in capsules
Results
Posted on the registry
  1. 19 Nov 2013: Trial registered
  2. 6 Feb 2014: Trial started
  3. 7 Jan 2015: Trial completed
  4. 2 Nov 2021: Trial results posted

NCT05741476: Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age

State
Under way
Phase
Phase 3
People
600 planned
Started
21 Feb 2023
Primary completion
6 Nov 2025
Arms
DBPC Treatment Period: DBV712 250 mcg, Open Label Extension Period: DBV712 250 mcg
Results
None posted
  1. 21 Feb 2023: Trial started
  2. 23 Feb 2023: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Also known as AR101 powder provided in capsules, Palforzia, Peanut Oral Immunotherapy - Liquid Extract, Peanut protein, Viaskin Peanut patch component peanut protein flour.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.